Considering the Sydney revised laboratory criteria of APS, only 17.8% (30/169) of patients in our study were positive for LA or aCL and/or anti-β2GPI, but when aPS/PT was evaluated as an additional parameter, 24.8% (41/169) of patients were aPL positive. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.